Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pluristem Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: xcentral1 who wrote (234)	11/12/2012 8:57:32 AM
From: idos	Respond to of 295

This comment by Professor Leigh Turner of the University of Minnesota Center for Bioethics about ethical issues related to that PSTI case is my take away from the story: "There are some valuable lessons here both for reporters as well as for consumers of news coverage of stem cell research and other areas of science that are routinely overhyped. Whose interests are served when press releases are issued? Is there something significant about timing of press releases? Are independent voices included in news coverage or do all quoted individuals have vested interests in promoting positive account of study results? Why is a press release being issued if results are based upon a single research participant or merely a few research subjects? And finally, what financial interests are swirling beneath the language of “miracles”, “cures”, and “lifesaving” interventions? These are questions reporters should ask and they are also questions those of us who read and otherwise consume the news should consider whenever we are confronted with dramatic claims floated on anecdotes, testimonials, and research “findings” based on meaningless sample sizes." ipscell.com